Human Genetics Identifies BACH2-NRF2 Axis in Fetal Hemoglobin Activation

Human genetics research has identified a critical molecular pathway involving the genes BACH2 and NRF2 that plays a significant role in the activation of fetal hemoglobin. This discovery, published online in the journal Nature on September 30, 2026, provides new insights into the complex mechanisms that control the production of different types of hemoglobin in the body. Hemoglobin is a protein in red blood cells responsible for carrying oxygen, and fetal hemoglobin (HbF) is the primary oxygen-carrying molecule produced by the fetus during pregnancy. After birth, the production of HbF typically declines and is replaced by adult hemoglobin (HbA). However, reactivating HbF production in adults is a key therapeutic strategy for treating certain hemoglobinopathies, such as sickle cell disease and beta-thalassemia, which are caused by mutations affecting HbA production.

The study elucidates the specific functions of BACH2 and NRF2 in this process. Researchers found that the protein encoded by the BACH2 gene acts as a repressor, restraining the activation of the fetal-haemoglobin-encoding γ-globin genes. In essence, BACH2 functions to keep the fetal hemoglobin genes switched off after birth. Conversely, the loss or reduced activity of BACH2 was observed to enhance the occupancy of the NRF2 protein at the chromatin, the complex of DNA and proteins that forms chromosomes within the nucleus of a cell. This enhanced NRF2 occupancy promotes the formation of "activation foci" at the γ-globin genes. These foci are specialized regions within the cell nucleus where gene activation processes are concentrated, suggesting that NRF2 plays a crucial role in initiating and facilitating the transcription of fetal hemoglobin genes when BACH2 is absent or suppressed.

This finding establishes a direct link between the BACH2-NRF2 axis and the regulation of fetal hemoglobin. The research suggests that manipulating the activity of either BACH2 or NRF2 could be a viable approach to therapeutically induce fetal hemoglobin production. By understanding how BACH2 restrains and NRF2 promotes γ-globin gene expression, scientists can explore targeted interventions. For instance, developing drugs that inhibit BACH2 or enhance NRF2 activity could potentially lead to new treatments for blood disorders characterized by insufficient adult hemoglobin. The precise mechanisms by which NRF2 binding to chromatin leads to the formation of these activation foci are areas for further investigation, but the genetic evidence strongly implicates this axis as a central regulator.

The implications of this research extend to the broader field of hematology and genetic therapy. The identification of specific genetic regulators like BACH2 and NRF2 offers precise targets for drug development. Future research will likely focus on the detailed molecular interactions between these proteins and the γ-globin gene locus, as well as exploring the safety and efficacy of modulating this pathway in preclinical models. The study's publication in Nature, a leading scientific journal, underscores the significance of these findings in advancing our understanding of hemoglobin switching and its potential therapeutic applications for millions of individuals affected by hemoglobin disorders worldwide. The doi for the publication is 10.1038/s41586-026-11113-2.